Trevi Therapeutics, Inc. (TRVI)

Over the past six months, Trevi Therapeutics' stock has been impacted by several key events. The stock has seen a significant increase over the past year. In August 2025, the company reported its second-quarter financial results and positive topline results from the Phase 2b CORAL trial. In November 2025, the company announced its third-quarter financial results and reiterated plans to initiate Phase 3 and Phase 2b programs in 2026. In December 2025, David Hastings was appointed as Chief Financial Officer. In January 2026, the company provided strategic updates ahead of the LifeSci Partners Corporate Access Event, including an upcoming meeting with the FDA and plans to initiate a Phase 2b trial. The stock experienced a decrease in the month leading up to January 14, 2026.

Trevi Therapeutics, Inc. currently generates no product revenue from drug sales, as Haduvio is still in development. Therefore, there is no traditional demand seasonality for its products or services. The company's financial stability is primarily sustained through capital raises and interest income from cash reserves.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio for neurologically mediated conditions. Their primary product candidate, Haduvio, is being developed to treat conditions like chronic cough in IPF and non-IPF ILD, refractory chronic cough, prurigo nodularis, pruritus in chronic liver disease, and levodopa-induced dyskinesia in Parkinson's disease patients. The company's success depends on the successful completion of Phase 3 trials and regulatory approval, as it currently generates no product revenue.

Trevi Therapeutics, Inc. primarily operates within the United States and is headquartered in New Haven, Connecticut.

Trevi Therapeutics' brand reputation appears to be positively influenced by its clinical trial successes. The company has received "Buy" ratings from analysts due to positive data from its Haduvio trials. News sentiment regarding the company's headlines is generally positive, and there have been no specific events identified that have negatively impacted its brand reputation.

Institutional investors hold a significant majority of Trevi Therapeutics, Inc. stock. Major institutional owners include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, Vanguard Group Inc, Viking Global Investors Lp, Vivo Capital, LLC, Marshall Wace, Llp, Morgan Stanley and Alliancebernstein L.p.. Individual investors hold a smaller percentage of the shares, and insiders own a notable portion of the stock, with James N. Topper owning the most shares among individuals.